Massry Prize

Rady Children's Hospital Appoints Rob Knight, Ph.D. as The Wolfe Family Endowed Chair in Microbiome Research at Rady Children's

Retrieved on: 
Thursday, June 15, 2023

Dr. Knight's appointment as Chair will lead to new, high-impact microbiome research and we look forward to seeing his findings improve care and outcomes for our patients, particularly those with hard-to-treat diseases."

Key Points: 
  • Dr. Knight's appointment as Chair will lead to new, high-impact microbiome research and we look forward to seeing his findings improve care and outcomes for our patients, particularly those with hard-to-treat diseases."
  • In collaboration with Rady Children's, Dr. Knight has investigated the role of the microbiome in pediatric patients with cystic fibrosis and chronic airway disease.
  • In 2017, Dr. Knight was honored with the highly prestigious Massry Prize and given the NIH Director's Pioneer Award for his microbiome research in 2019.
  • He has authored two books on microbiome research and is a co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc.

IFF’s Philippe Horvath Inducted into The National Inventors Hall of Fame

Retrieved on: 
Monday, January 9, 2023

Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.

Key Points: 
  • Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.
  • Applying this research to enhance starter cultures in the dairy industry, Horvath and research partner Rodolphe Barrangou improved the world’s food supply and laid the foundation for the field of gene editing.
  • “We are proud of the achievements made by Philippe and the entire CRISPR team.
  • “I am deeply honored to be selected by the National Inventors Hall of Fame to represent the pioneering work our team has done,” said Horvath.

Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences

Retrieved on: 
Wednesday, October 23, 2019

Ionis' antisense technology has created the life-changing medicines SPINRAZA, TEGSEDI and WAYLIVRA and a pipeline of more than 40 first-in-class or best-in-class therapies focused on rare and common diseases.

Key Points: 
  • Ionis' antisense technology has created the life-changing medicines SPINRAZA, TEGSEDI and WAYLIVRA and a pipeline of more than 40 first-in-class or best-in-class therapies focused on rare and common diseases.
  • "I am deeply honored to accept the Massry Prize.
  • The Meira and Shaul G. Massry Foundation established the Massry Prize in 1996 to recognize outstanding contributions to the biomedical sciences and the advancement of health.
  • More than a third of Massry Prize recipients (17) have also won the Nobel Prize.

FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

Retrieved on: 
Monday, October 7, 2019

SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the companys Scientific Advisory Board, has been awarded the 2019 Nobel Prize in Physiology or Medicine.

Key Points: 
  • SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the companys Scientific Advisory Board, has been awarded the 2019 Nobel Prize in Physiology or Medicine.
  • The Nobel Assembly announced this morning that the 2019 Nobel Prize in Physiology or Medicine would be awarded jointly to William G. Kaelin, Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.
  • Bills transformative discovery led to an elucidation of the molecular signaling pathway that enables cells to respond to changing oxygen levels by regulating gene expression, said Gail Walkinshaw, FibroGens Vice President, Research.
  • With this knowledge, we have been able to explore ways to therapeutically harness the natural adaptive mechanisms that have evolved to respond to altered oxygen levels in the body.